Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
NCT06351657
Recruiting
The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years. The main objectives of this study are: * Assess the individual progression rate of a patient in non-foveal, non-vision compromising atrophic AMD and assess personalized risk of progression based on imaging. * Identify and quantify focal and global alterations in the retina in regard to d... Read More
Gender:
ALL
Ages:
Between 55 years and 99 years
Trial Updated:
05/12/2025
Locations: Medical University of Vienna, Vienna, Not set +6 locations
Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Register for Updates
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
NCT06165510
Recruiting
A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: St Bartholomew's Hospital, London, Not set
Conditions: Persistent Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrium; Fibrillation, Atrial Arrhythmia
Register for Updates
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Hospital Fundación Jiménez Diaz, Madrid, Not set +2 locations
Conditions: Relapsed or Refractory B-cell Malignancies
Register for Updates
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057
Recruiting
This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to \<18 years) patients with DMD. 138 patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months. * Planned screening duration: approximately 4 weeks (±14 days) * Planned treatment duration: 18 months (approximately 72 weeks) * Planned follow-up duration: 4 weeks (±7 days) (for patients... Read More
Gender:
MALE
Ages:
Between 9 years and 17 years
Trial Updated:
05/09/2025
Locations: Universitaire Ziekenhuizen Leuven, Leuven, Not set +19 locations
Conditions: Duchenne Muscular Dystrophy
Register for Updates
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT04982393
Recruiting
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Gender:
ALL
Ages:
All
Trial Updated:
05/09/2025
Locations: Clinical Trial Site, Phoenix, Arizona +29 locations
Conditions: Primary Hyperoxaluria Type 1
Register for Updates
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Epilepsy Involving the Temporal Lobe Region.
NCT04526418
Recruiting
The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in U... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/09/2025
Locations: University of California, Los Angeles, California +12 locations
Conditions: Epilepsy
Register for Updates
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.
NCT06727565
Recruiting
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Siteman Cancer Center, Saint Louis, Missouri +24 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05776472
Recruiting
This is a 36-month, long-term, multicenter, observational study designed to describe the real world effectiveness of pegcetacoplan in patients with PNH. Patients meeting the eligibility criteria will be enrolled in the study and followed prospectively for approximately 36 months. Patient data will be collected from start of pegcetacoplan treatment to end of follow-up. Retrospective data on pegcetacoplan will be captured from the time of pegcetacoplan treatment initiation. Pegcetacoplan treatment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Liverpool Hospital, Liverpool, New South Wales +74 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Register for Updates
Intra-operative Detection of Positive Margins in Breast Surgery
NCT06977698
Recruiting
In this project, we will develop a unique OCT-Raman system based on a selective sampling approach optimised for high-resolution analysis of whole lumpectomy specimens. The aim of using OCT is not to detect the cancer but to identify the adipose tissue, such that the large adipose tissue regions are excluded from any further measurements by Raman spectroscopy. While OCT has a limited ability to distinguish between tumour and surrounding normal stroma, adipose tissue has a distinctive appearance... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
05/09/2025
Locations: Nottingham university hospitals, Nottingham, Not set
Conditions: Breast Cancer Invasive
Register for Updates
Adult SMA Research and Clinical Hub
NCT06978985
Recruiting
Adult SMA REACH is a data collection study aiming to gain a better understanding of the impact of standards of care and new treatments on the natural history of Spinal Muscular Atrophy (SMA). This study is sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust. Adult SMA REACH is funded by Biogen and Roche. Currently, there are three drug treatments available for SMA in the UK: Zolgensma, Nusinersen and Risdiplam. Zolgensma is the only approved drug - Nusinersen and Risdiplam are c... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/09/2025
Locations: University Hospitals Birmingham NHS Foundation Trust, Birmingham, Not set +17 locations
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)
NCT06907784
Recruiting
It is known that individuals respond differently to the same medicine with some people benefitting, some experiencing no effect and others suffering side-effects or even coming to harm. Some of the differences in response to medications can be explained by our genes. Genes are short sections of DNA. Each individual has over 20,000 different genes. Genes carry instructions for making the proteins needed to build things within the body including the sites where medicines act. Pharmacogenomics is t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Queen Elizabeth University Hospital, Glasgow, Not set
Conditions: Pharmacogenomic Drug Interaction
Register for Updates
Post-marketing Clinical Follow-up for Long-term Use of Intranasal Kinetic Oscillation in Subjects With Chronic Migraine
NCT05843721
Recruiting
An non controlled, long term, multi center investigation
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/08/2025
Locations: Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden UniversitätsSchmerzCentrum, Dresden, Not set +15 locations
Conditions: Chronic Migraine
Register for Updates